Ghrelin Infusion Improved Heart Function in Chronic Heart Failure Patients

This was a double-blind, placebo-controlled study in 12 patients with chronic heart failure. Each patient received either an intravenous infusion of synthetic human ghrelin (0.1 µg/kg/min) or placebo. Researchers measured hemodynamic parameters (blood pressure, cardiac index, stroke volume, pulmonary pressures), renal function (urine volume, sodium excretion, creatinine clearance), and hormonal responses (GH, epinephrine, ACTH, cortisol, prolactin) during and after infusion.

Heart failure treatments that improve cardiac output without worsening kidney function or raising heart rate are highly valuable. This early study showed ghrelin could do exactly that, suggesting this peptide might have therapeutic potential for heart failure beyond its well-known roles in appetite and growth hormone regulation. It opened a new avenue of cardiovascular peptide research.

This was one of the first studies to demonstrate ghrelin's direct cardiovascular benefits in human heart failure patients. It supported the idea that ghrelin acts through GH-independent mechanisms to dilate blood vessels and improve cardiac function. This research contributed to ongoing interest in peptide-based approaches to heart failure treatment and helped redefine ghrelin as more than just a hunger hormone.

The study included only 12 patients, which limits statistical power and generalizability. It measured acute effects of a single infusion rather than long-term outcomes. The study did not investigate the mechanism behind ghrelin's hemodynamic effects or whether repeated dosing would sustain benefits. As a 2001 study, newer heart failure treatments have since emerged that may change the clinical context.